Stock Alert: Atreca Down 18%

(RTTNews) - Shares of Atreca, Inc. (BCEL) are currently losing nearly 18% on Thursday morning despite no stock-specific news.

BCEL is currently trading at $15.11, down $3.31 or 17.96%, on the Nasdaq.

Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types.

The company on Wednesday announced the pricing of its previously announced underwritten public offering of 7 million Class A common stock and 781 thousand Class B common stock, each at a price to the public of $16.00 per share.

Gross proceeds to Atreca from the offering are expected to be $125.0 million.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More